Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden

被引:1
|
作者
Teni, Fitsum Sebsibe [1 ,2 ]
Machado, Alejandra [2 ]
Fink, Katharina [3 ]
Gyllensten, Hanna [4 ]
Hillert, Jan [3 ]
Friberg, Emilie [2 ]
机构
[1] Karolinska Inst, Dept Clin Neurosci, Div Insurance Med, SE-17177 Stockholm, Sweden
[2] Karolinska Inst, Dept Clin Neurosci, Div Insurance Med, Stockholm, Sweden
[3] Karolinska Inst, Dept Clin Neurosci, Div Neurol, Stockholm, Sweden
[4] Univ Gothenburg, Inst Hlth & Care Sci, Sahlgrenska Acad, Gothenburg, Sweden
基金
瑞典研究理事会;
关键词
Disease-modifying drugs; high-efficacy DMTs; sick leave; cluster analysis;
D O I
10.1177/13524585231225929
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Disease-modifying therapies (DMTs) have led to improved health and work productivity among people with multiple sclerosis (PwMS). Objectives: To describe trajectories of recent DMT use and their association with sickness absence and/or disability pension (SADP) among PwMS in Sweden. Methods: A longitudinal register-based study was conducted among 1395 PwMS with treatment start in 2014/2015. While DMT use over 5 years was assessed using sequence analysis resulting in four clusters, a 7-year (Y-2 toY(4)) trend of SADP was analyzed using zero-inflated negative binomial regression. Results: Four clusters of DMT use trajectories were identified: long-term non-high-efficacy (483, 34.6%), long-term high-efficacy (572, 41%), escalation (221, 15.8%), and discontinuation (119, 8.5%). Progressive MS and higher expanded disability status scale scores were associated with the escalation, long-term high-efficacy, or discontinuation clusters. PwMS in the long-term high-efficacy and escalation clusters had higher likelihood of being on SADP. However, PwMS initiating high-efficacy DMTs demonstrated steeper decline in SADP than others. Conclusion: Using sequence analysis, this study showed recent DMT use trajectories among PwMS where initiation of high-efficacy DMTs has become more common. The trend of SADP was stable and lower in those using non-high-efficacy DMTs and larger improvements were shown in those initiating high-efficacy DMTs.
引用
收藏
页码:419 / 431
页数:13
相关论文
共 50 条
  • [1] Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden
    Teni, Fitsum Sebsibe
    Machado, Alejandra
    Murley, Chantelle
    He, Anna
    Fink, Katharina
    Gyllensten, Hanna
    Glaser, Anna
    Alexanderson, Kristina
    Hillert, Jan
    Friberg, Emilie
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 69
  • [2] Trajectories of disease-modifying therapies and associated sickness absence and disability pension among people with multiple sclerosis
    Teni, F. S.
    Machado, A.
    Murley, C.
    He, A.
    Fink, K.
    Gyllensten, H.
    Glaser, A.
    Alexanderson, K.
    Hillert, J.
    Friberg, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 672 - 673
  • [3] Sickness absence and disability pension among Multiple Sclerosis patients in Sweden
    Tinghog, Petter
    Kjeldgard, L.
    Hillert, J.
    Alexanderson, K.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2012, 22 : 215 - 215
  • [4] Sickness absence and disability pension among multiple sclerosis patients in Sweden
    Tinghog, P.
    Kjeldgard, L.
    Hillert, J.
    Alexanderson, K.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 316 - 317
  • [5] Patterns and Trends of Healthcare Utilization Among People with Multiple Sclerosis in the Age of Disease-Modifying Modifying Therapy
    Isfort, Michael C.
    Xia, Zongqi
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 53 - 54
  • [6] Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation
    Bosma, Astrid R.
    Murley, Chantelle
    Aspling, Jenny
    Hillert, Jan
    Schaafsma, Frederieke G.
    Anema, Johannes R.
    Boot, Cecile R. L.
    Alexanderson, Kristina
    Machado, Alejandra
    Friberg, Emilie
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (09) : 1402 - 1413
  • [7] Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy
    Achiron, Anat
    Sarova-Pinhas, Ida
    Magalashvili, David
    Stern, Yael
    Gal, Aviva
    Dolev, Mark
    Menascu, Shay
    Harari, Gil
    Gurevich, Michael
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (13) : 1746 - 1753
  • [8] Longitudinal changes in sickness absence and disability pension, and associations between disability pension and disease-specific and contextual factors and functioning, in people with multiple sclerosis
    Chruzander, Charlotte
    Tinghog, Petter
    Ytterberg, Charlotte
    Holmqvist, Lotta Widen
    Alexanderson, Kristina
    Hillert, Jan
    Johansson, Sverker
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 367 : 319 - 325
  • [9] Disease-modifying therapy for multiple sclerosis
    Holmoy, Trygve
    Myhr, Kjell-Morten
    Bo, Lars
    Nygaard, Gro Owren
    [J]. TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2021, 141 (08) : 723 - 726
  • [10] Disease-modifying therapy for multiple sclerosis
    Klineova, Sylvia
    Mitiku, Nesanet
    Miller, Aaron E.
    [J]. FUTURE NEUROLOGY, 2015, 10 (03) : 253 - 279